Patient-specific tumor neoantigen peptide-HLA complex (NeoAg-HLA complex)

Patient-specific tumor neoantigen peptide-HLA complexes are unique molecular targets formed when mutated proteins within a tumor are processed into short peptides and displayed on the cell surface by Human Leukocyte Antigen (HLA) molecules (Schumacher & Schreiber, 2015). These neoantigens arise from somatic mutations—such as non-synonymous single nucleotide variants (SNVs), insertions/deletions (indels), or chromosomal translocations—that are entirely absent from the patient's healthy genome (Sahin & Türeci, 2018). Because these complexes are recognized as foreign by the immune system, they serve as the primary targets for personalized cancer immunotherapies, including neoantigen vaccines and adoptive T-cell transfers (Ott et al., 2017). By specifically targeting these 'non-self' epitopes, therapies aim to induce a robust, tumor-specific T-cell response while minimizing the risk of off-target damage to normal tissues. The clinical utility of these targets is currently being explored in various solid tumors, often in combination with immune checkpoint inhibitors to overcome local immunosuppression (Blass & Ott, 2021). Therapeutic strategies involve sequencing a patient's tumor and healthy DNA to identify mutations, using bioinformatic algorithms to predict which mutant peptides will bind strongly to the patient's specific HLA alleles, and then manufacturing a bespoke vaccine (Hu et al., 2021). While highly promising, challenges remain regarding the speed of manufacturing, the accurate prediction of immunogenic epitopes, and the potential for tumors to escape immune pressure by downregulating HLA expression or losing the targeted mutations (Gubin et al., 2015).

Other names

Tumor-specific neoantigenNeoepitope-HLA complexPersonalized tumor antigenMutant peptide-MHC complexTSA-HLA complex

Personalized neoantigen therapies work by delivering the genetic code or synthetic peptides corresponding to a patient's unique tumor mutations. These neoantigens are processed and presented by antigen-presenting cells (APCs) via HLA molecules to T cells. This process primes and activates de novo neoantigen-specific CD8+ and CD4+ T-cell responses, which then circulate and specifically recognize the same neoantigen-HLA complexes on the surface of tumor cells, leading to targeted cell lysis (Sahin & Türeci, 2018; Ott et al., 2017).